ASP Isotopes Inc. Commences Commercial Production of Enriched Carbon-14 at its First Aerodynamic Separation Process (ASP) Enrichment Facility
ASP Isotopes (NASDAQ: ASPI) has initiated commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) facility in Pretoria, South Africa. The company expects to begin shipping products by mid-2025. A multi-year take-or-pay contract with Canadian customer RC-14 Inc. is valued at minimum $2.4 million annually.
The facility's commercial production, initially planned for 2024, faced delays due to international shipping complications affecting specialized feedstock supply. Carbon-14, primarily used as a radiolabel in drug discovery and metabolism studies, has historically been exclusively supplied by Russia, with existing shortages intensified by recent global disruptions.
ASP Isotopes (NASDAQ: ASPI) ha avviato la produzione commerciale di Carbonio-14 arricchito presso il suo primo stabilimento di Aerodynamic Separation Process (ASP) a Pretoria, Sudafrica. L'azienda prevede di iniziare a spedire i prodotti entro la metà del 2025. Un contratto di take-or-pay pluriennale con il cliente canadese RC-14 Inc. è valutato a un minimo di 2,4 milioni di dollari all'anno.
La produzione commerciale dello stabilimento, inizialmente prevista per il 2024, ha subito ritardi a causa di complicazioni nella spedizione internazionale che hanno influito sulla fornitura di materie prime specializzate. Il Carbonio-14, utilizzato principalmente come radiomarca nei studi di scoperta di farmaci e metabolismo, è stato storicamente fornito esclusivamente dalla Russia, con le carenze esistenti amplificate dalle recenti interruzioni globali.
ASP Isotopes (NASDAQ: ASPI) ha iniciado la producción comercial de Carbono-14 enriquecido en su primera instalación de Proceso de Separación Aerodinámica (ASP) en Pretoria, Sudáfrica. La compañía espera comenzar a enviar productos a mediados de 2025. Un contrato de take-or-pay a varios años con el cliente canadiense RC-14 Inc. está valorado en un mínimo de 2,4 millones de dólares anuales.
La producción comercial de la instalación, inicialmente planificada para 2024, enfrentó retrasos debido a complicaciones en el envío internacional que afectaron el suministro de materia prima especializada. El Carbono-14, utilizado principalmente como radiomarcador en estudios de descubrimiento de medicamentos y metabolismo, ha sido históricamente suministrado exclusivamente por Rusia, con las carencias existentes intensificadas por las recientes interrupciones globales.
ASP Isotopes (NASDAQ: ASPI)는 남아프리카 프리토리아에 있는 첫 번째 공기역학적 분리 공정(ASP) 시설에서 농축된 탄소-14의 상업 생산을 시작했습니다. 회사는 2025년 중반까지 제품 배송을 시작할 것으로 예상하고 있습니다. 캐나다 고객 RC-14 Inc.와의 다년간의 테이크 오르 페이 계약은 최소 연간 240만 달러의 가치가 있습니다.
2024년으로 계획된 시설의 상업 생산은 특수 원자재 공급에 영향을 미친 국제 배송 문제로 인해 지연되었습니다. 탄소-14는 주로 약물 발견 및 대사 연구에서 방사성 표지자로 사용되며, 역사적으로 러시아에서만 공급되어 왔으며, 최근의 글로벌 중단으로 인해 기존의 부족이 심화되었습니다.
ASP Isotopes (NASDAQ: ASPI) a lancé la production commerciale de carbone-14 enrichi dans sa première installation de processus de séparation aérodynamique (ASP) à Pretoria, en Afrique du Sud. L'entreprise prévoit de commencer à expédier des produits d'ici la mi-2025. Un contrat de take-or-pay pluriannuel avec le client canadien RC-14 Inc. est évalué à un minimum de 2,4 millions de dollars par an.
La production commerciale de l'installation, initialement prévue pour 2024, a été retardée en raison de complications d'expédition internationales affectant l'approvisionnement en matières premières spécialisées. Le carbone-14, principalement utilisé comme radiomarqueur dans la découverte de médicaments et les études de métabolisme, a historiquement été fourni exclusivement par la Russie, les pénuries existantes étant intensifiées par les récentes perturbations mondiales.
ASP Isotopes (NASDAQ: ASPI) hat die kommerzielle Produktion von angereichertem Kohlenstoff-14 in seiner ersten Einrichtung für den Aerodynamischen Trennprozess (ASP) in Pretoria, Südafrika, aufgenommen. Das Unternehmen erwartet, bis Mitte 2025 mit dem Versand von Produkten zu beginnen. Ein mehrjähriger Take-or-Pay-Vertrag mit dem kanadischen Kunden RC-14 Inc. hat einen Mindestwert von 2,4 Millionen Dollar jährlich.
Die kommerzielle Produktion der Einrichtung, die ursprünglich für 2024 geplant war, verzögerte sich aufgrund internationaler Versandkomplikationen, die die Versorgung mit speziellen Rohstoffen beeinträchtigten. Kohlenstoff-14, das hauptsächlich als Radiomarker in der Arzneimittelentdeckung und Stoffwechselstudien verwendet wird, wurde historisch gesehen ausschließlich von Russland geliefert, wobei die bestehenden Engpässe durch jüngste globale Störungen verstärkt wurden.
- Secured $2.4M annual minimum revenue through take-or-pay contract
- Successfully commenced commercial production of Carbon-14
- Strong order book from global customers
- Positioned as alternative supplier to Russian monopoly
- Production delayed from 2024 due to supply chain issues
- Dependency on customer-supplied feedstock
Insights
ASP Isotopes' commencement of commercial Carbon-14 production represents a critical inflection point in the company's transition from development stage to revenue generation. The secured
This development carries strategic importance beyond its immediate financial impact. ASPI is breaking Russia's historical monopoly on enriched Carbon-14 supply, positioning itself as the Western alternative in a critical supply chain. With existing global shortages and disruptions, ASPI enters a seller's market with significant pricing power potential.
The successful deployment of their Aerodynamic Separation Process technology for Carbon-14 serves as an important proof-of-concept for ASPI's broader business model. Management indicates the technology is applicable to various isotopes, suggesting this first facility could be the foundation of a much larger isotope production portfolio. Carbon-14's essential role in pharmaceutical research and development creates a stable, recession-resistant customer base.
While representing less than
- The Company has commenced commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) enrichment facility.
- The Company expects to ship commercial product around the middle of the year.
- The Company previously entered into a multi-year, take-or-pay contract with a Canadian customer, valued at a minimum of approximately
WASHINGTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has started commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) enrichment facility in Pretoria, South Africa.
The Company’s Carbon-14 enrichment facility was the Company’s first enrichment facility constructed in South Africa and was expected to start commercial production during 2024. However, the specialized feedstock, supplied to the Company in South Africa by the customer, was delayed primarily due to international shipping complications.
The Company previously announced that it has entered into a multi-year take-or-pay contract with a Canadian customer, RC-14 Inc., that has a minimum commitment of approximately
Carbon-14 is the most frequently used radiolabel for drug discovery, drug metabolism, and pharmacokinetics. Carbon naturally exists in many drug molecules, and thus it provides better radiolabelling sites. Radiolabelling is a scientific technique used to track the passage of a molecule. The technique incorporates a radioisotope through a reaction, cell, organism, biological system, or metabolic pathway. Russia has historically been responsible for the entire global supply of enriched Carbon-14 and already existing shortages have been exacerbated with persistent global disruptions during recent years.
"The World is in urgent need of an alternative supplier of enriched Carbon-14. We have had considerable interest from customers, and we have built a strong order book from many customers around the world", said Stephane Leduc, Chief Executive Officer of RC-14 and General Manager of CCNuclear.
"The ASP Process is ideally suited to enriching a wide range of isotopes, particularly light isotopes, such as Carbon-14. We look forward to helping solve the supply chain issues that have plagued the world during recent years. We are excited to finally be in commercial production of this critical isotope," said Paul Mann, Chairman and CEO of ASP Isotopes.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a pre-commercial stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to, statements relating to the commencement of supply of isotopes to customers and the application of new technology for the enrichment of isotopes, and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including our reliance on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions and contracts; dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry; and the factors disclosed in Part I, Item 1A. “Risk Factors” of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and any amendments thereto and in the company’s subsequent reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
FAQ
What is the annual value of ASPI's Carbon-14 contract with RC-14 Inc?
When will ASPI begin shipping Carbon-14 from its South African facility?
Why was ASPI's Carbon-14 production delayed from 2024?
Where is ASPI's first Carbon-14 production facility located?
